The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M; Eur J Haematol. 2015; 95(6):538-544

Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.

Aschauer, G; Greil, R; Linkesch, W; Nösslinger, T; Stauder, R; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Keil, F; Petzer, A; Clin Lymphoma Myeloma Leuk. 2015; 15(11):e143-e149

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Ludwig, H; Rauch, E; Kuehr, T; Adam, Z; Weißmann, A; Kasparu, H; Autzinger, EM; Heintel, D; Greil, R; Poenisch, W; Müldür, E; Zojer, N; Haematologica. 2015; 100(3):385-391

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.

Tiede, A; Klamroth, R; Scharf, RE; Trappe, RU; Holstein, K; Huth-Kühne, A; Gottstein, S; Geisen, U; Schenk, J; Scholz, U; Schilling, K; Neumeister, P; Miesbach, W; Manner, D; Greil, R; von Auer, C; Krause, M; Leimkühler, K; Kalus, U; Blumtritt, JM; Werwitzke, S; Budde, E; Koch, A; Knöbl, P; Blood. 2015; 125(7):1091-1097

Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.

Kocher, F; Hilbe, W; Seeber, A; Pircher, A; Schmid, T; Greil, R; Auberger, J; Nevinny-Stickel, M; Sterlacci, W; Tzankov, A; Jamnig, H; Kohler, K; Zabernigg, A; Frötscher, J; Oberaigner, W; Fiegl, M; Lung Cancer. 2015; 87(2):193-200

Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.

Nachbaur, D; Angelova, O; Orth-Holler, D; Ditlbacher, A; Lackner, M; Auberger, J; Lass-Florl, C EUR J HAEMATOL. 2015; 94(3): 258-264.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos, F; Thépot, S; Pleyer, L; Maurillo, L; Itzykson, R; Bargay, J; Stauder, R; Venditti, A; Seegers, V; Martínez-Robles, V; Burgstaller, S; Récher, C; Debén, G; Gaidano, G; Gardin, C; Musto, P; Greil, R; Sánchez-Guijo, F; Fenaux, P; Leuk Res. 2015; 39(3):296-306

Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.

Wasle, I; Gamerith, G; Kocher, F; Mondello, P; Jaeger, T; Walder, A; Auberger, J; Melchardt, T; Linkesch, W; Fiegl, M; Mian, M; Ann Hematol. 2015; 94(4): 593-601.

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Sochalska, M; Tuzlak, S; Egle, A; Villunger, A; FEBS J. 2015; 282(5): 834-849.

B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Zaborsky, N; Holler, C; Geisberger, R; Asslaber, D; Gassner, FJ; Egger, V; Piñón-Hofbauer, J; Kocher, T; Hartmann, TN; Greil, R; Egle, A; Haematologica. 2015; 100(8):e307-e310